File(s) not publicly available
New and future developments of therapy for asthma in children
chapterposted on 2023-02-03, 02:29 authored by Peter Sly, C M Jones
Treatment of childhood asthma has not changed substantially in recent decades, with no truly new drugs having been introduced since the turn of the last century. Mainstream therapy consists largely of inhaled corticosteroids in combination with β-agonists. Montelukast has a role in treating viral-induced wheeze in younger children and in preventing exercise-induced asthma. Review of the currently registered clinical trials for childhood asthma does not reveal any exciting new drug prospects. In recognition of the generally poor adherence with asthma therapy, a substantial research effort is underway to test strategies designed to improve asthma management with existing medications. Novel drugs with potential activity in asthma are currently being trialled in adults with asthma and some of these may eventually find their way into paediatric use. However, themost exciting advances in childhood asthma are likely to come from trials designed to prevent asthma. While several potential strategies can be identified from epidemiological studies, well conducted randomised clinical trials will be required to determine whether they are effective. © ERS 2012.
Pagination224 - 234
CategoriesNo categories selected
Science & TechnologyLife Sciences & BiomedicineAllergyPediatricsRespiratory SystemAsthmaclinical trialscomplementary and alternative medicinedrug development pipelineprevention of asthmaINHALED CORTICOSTEROIDSPOTENTIAL TREATMENTVIRAL-INFECTIONSDRUG DEVELOPMENTDOUBLE-BLINDHIGH-RISKANTI-IGECHILDHOODDISEASEADULTS